The approved drugs for Alzheimer’s disease do not address the underlying cause of the disease, but instead treat only the symptoms. However, there is a vast array of experimental treatments that are ...

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

A groundbreaking discovery by scientists at Japan’s RIKEN Center for Brain Science has revealed an unexpected link between dopamine and Alzheimer’s disease. This revelation could mark a major ...

(“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease ...

"There is still no cure for Alzheimer's, and that's important to understand," Jing said. "But this treatment can help people maintain their independence and thinking skills longer and give people ...

It is believed most humans are ... First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ...

Preclinical models are research tools used to test new treatments before trying them ... single behaviour is guaranteed to prevent dementia - but there's lots of evidence to suggest that making ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Once there, the virus can change the immune system and contribute to other changes associated with Alzheimer's disease. This virus may be a target for antiviral treatments. Arizona State ...

Due, in part, to the logical nature of the approach, combination therapy is already widely used in clinical practice. Although compounds with a combined cholinergic–glutamatergic action have ...